Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADMA ADMA Biologics	$18.40 +4.5%	$20.69	$10.21 ▼ $25.67	$4.20B	0.47	3.70 million shs	4.47 million shs
KRYS Krystal Biotech	$142.58 +0.1%	$141.26	$122.80 ▼ $219.34	$4.12B	0.65	288,963 shs	321,736 shs
NAGE Niagen Bioscience	$13.82 +3.1%	$10.66	$2.40 ▼ $14.49	$1.06B	2.08	893,638 shs	856,298 shs
ZLAB Zai Lab	$36.19 -2.1%	$33.35	$16.01 ▼ $44.34	$4.08B	0.96	902,935 shs	563,086 shs

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADMA ADMA Biologics	+4.55%	+1.49%	-7.49%	-9.18%	+69.74%
KRYS Krystal Biotech	+0.06%	+7.94%	+12.76%	-22.48%	-21.74%
NAGE Niagen Bioscience	+3.06%	+0.29%	+30.38%	+104.14%	+406.23%
ZLAB Zai Lab	-2.08%	-2.00%	+16.67%	-2.95%	+101.39%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADMA ADMA Biologics	3.6588 of 5 stars	3.7	1.0	0.0	1.9	2.5	3.1
KRYS Krystal Biotech	4.5444 of 5 stars	3.5	1.0	4.7	3.2	2.5	1.9
NAGE Niagen Bioscience	1.4138 of 5 stars	3.5	0.0	0.0	2.5	0.0	0.0
ZLAB Zai Lab	2.0062 of 5 stars	3.4	1.0	0.0	2.5	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADMA ADMA Biologics	3.33	Buy	$27.67	50.36% Upside
KRYS Krystal Biotech	3.00	Buy	$211.13	48.07% Upside
NAGE Niagen Bioscience	3.00	Buy	$19.50	41.10% Upside
ZLAB Zai Lab	2.75	Moderate Buy	$47.37	30.88% Upside

Current Analyst Ratings Breakdown

Latest NAGE, ADMA, KRYS, and ZLAB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/24/2025	KRYS Krystal Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$240.00
6/10/2025	NAGE Niagen Bioscience	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$13.00 ➝ $16.00
6/6/2025	NAGE Niagen Bioscience	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $23.00
5/27/2025	NAGE Niagen Bioscience	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$13.00
5/16/2025	KRYS Krystal Biotech	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$215.00 ➝ $155.00
5/8/2025	ADMA ADMA Biologics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Strong-Buy ➝ Strong-Buy	$25.00 ➝ $32.00
5/7/2025	KRYS Krystal Biotech	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$195.00 ➝ $189.00
5/7/2025	KRYS Krystal Biotech	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$219.00 ➝ $219.00
5/6/2025	KRYS Krystal Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$240.00 ➝ $240.00
4/28/2025	KRYS Krystal Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$221.00 ➝ $240.00
3/27/2025	ZLAB Zai Lab	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight

(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADMA ADMA Biologics	$426.45M	10.30	$0.57 per share	32.52	$1.48 per share	12.43
KRYS Krystal Biotech	$290.52M	14.18	$4.64 per share	30.73	$32.90 per share	4.33
NAGE Niagen Bioscience	$99.60M	10.93	$0.06 per share	226.71	$0.60 per share	23.03
ZLAB Zai Lab	$398.99M	10.01	N/A	N/A	$7.68 per share	4.71

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADMA ADMA Biologics	$197.67M	$0.85	21.65	26.67	N/A	45.01%	47.16%	30.51%	8/6/2025 (Estimated)
KRYS Krystal Biotech	$89.16M	$4.16	34.27	14.14	N/A	37.17%	14.64%	13.28%	8/4/2025 (Estimated)
NAGE Niagen Bioscience	$8.55M	$0.17	81.29	∞	N/A	13.07%	19.06%	12.20%	N/A
ZLAB Zai Lab	-$257.10M	-$2.49	N/A	N/A	N/A	-60.26%	-33.35%	-23.28%	8/5/2025 (Estimated)

Latest NAGE, ADMA, KRYS, and ZLAB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	ZLAB Zai Lab	-$0.50	-$0.45	+$0.05	-$0.45	$118.40 million	$106.49 million
5/7/2025	Q1 2025	ADMA ADMA Biologics	$0.16	$0.14	-$0.02	$0.11	$116.40 million	$114.80 million
5/6/2025	Q1 2025	KRYS Krystal Biotech	$1.38	$1.20	-$0.18	$1.20	$98.66 million	$88.18 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADMA ADMA Biologics	N/A	N/A	N/A	N/A	N/A
KRYS Krystal Biotech	N/A	N/A	N/A	N/A	N/A
NAGE Niagen Bioscience	N/A	N/A	N/A	N/A	N/A
ZLAB Zai Lab	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADMA ADMA Biologics	0.22	6.58	3.36
KRYS Krystal Biotech	N/A	9.65	9.27
NAGE Niagen Bioscience	N/A	3.66	3.12
ZLAB Zai Lab	N/A	3.26	3.09

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADMA ADMA Biologics	75.68%
KRYS Krystal Biotech	86.29%
NAGE Niagen Bioscience	15.41%
ZLAB Zai Lab	41.65%

Insider Ownership

Company	Insider Ownership
ADMA ADMA Biologics	3.50%
KRYS Krystal Biotech	13.70%
NAGE Niagen Bioscience	9.39%
ZLAB Zai Lab	4.96%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADMA ADMA Biologics	530	238.73 million	230.38 million	Optionable
KRYS Krystal Biotech	210	28.90 million	24.94 million	Optionable
NAGE Niagen Bioscience	120	78.77 million	71.37 million	N/A
ZLAB Zai Lab	1,869	110.33 million	104.86 million	Optionable

NAGE, ADMA, KRYS, and ZLAB Headlines

Recent News About These Companies

Cantor Fitzgerald Expects Reduced Earnings for Zai Lab

June 26 at 2:21 AM | americanbankingnews.com

Analysts Offer Predictions for Zai Lab FY2025 Earnings

June 25 at 6:12 AM | marketbeat.com

Insider Selling: Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Director Sells 13,814 Shares of Stock

June 24 at 4:39 AM | insidertrades.com

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Director William Lis Sells 13,814 Shares

June 23, 2025 | marketbeat.com

Zai Lab (NASDAQ:ZLAB) Shares Gap Up - Still a Buy?

June 23, 2025 | marketbeat.com

Zai Lab (ZLAB) Delivers Positive ZL-1503 Trial Results in Treatment of Atopic Dermatitis

June 20, 2025 | msn.com

Zai Lab (NASDAQ:ZLAB) Shares Down 5.4% - Time to Sell?

June 20, 2025 | marketbeat.com

Mission Wealth Management LP Buys Shares of 20,000 Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB)

June 18, 2025 | marketbeat.com

Zai Lab (NASDAQ:ZLAB) Shares Gap Down - Here's Why

June 17, 2025 | marketbeat.com

Zai Lab (NASDAQ:ZLAB) versus Antibe Therapeutics (OTCMKTS:ATBPD) Head to Head Comparison

June 17, 2025 | americanbankingnews.com

Zai Lab Presents New Preclinical Data for ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis, at EAACI Congress 2025

June 13, 2025 | finance.yahoo.com

Zai Lab (NASDAQ:ZLAB) Shares Gap Up - Time to Buy?

June 12, 2025 | marketbeat.com

Cantor Fitzgerald Forecasts Zai Lab FY2026 Earnings

June 11, 2025 | marketbeat.com

Zai Lab (NASDAQ:ZLAB) Sets New 1-Year High - Here's What Happened

June 10, 2025 | marketbeat.com

Two Sigma Investments LP Trims Stock Holdings in Zai Lab Limited (NASDAQ:ZLAB)

June 8, 2025 | marketbeat.com

Yajing Chen Sells 9,618 Shares of Zai Lab Limited (NASDAQ:ZLAB) Stock

June 5, 2025 | marketbeat.com

Zai Lab Limited (NASDAQ:ZLAB) CFO Sells $288,540.00 in Stock

June 5, 2025 | insidertrades.com

Bank of America Corp DE Has $1.63 Million Stock Holdings in Zai Lab Limited (NASDAQ:ZLAB)

June 5, 2025 | marketbeat.com

Zai Lab (NASDAQ:ZLAB) Shares Gap Up - Here's Why

June 4, 2025 | marketbeat.com

Squarepoint Ops LLC Acquires Shares of 27,961 Zai Lab Limited (NASDAQ:ZLAB)

June 3, 2025 | marketbeat.com

Legacy Wealth Asset Management LLC Buys Shares of 22,285 Zai Lab Limited (NASDAQ:ZLAB)

June 2, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
3 Defense Stocks That Will Profit From a Golden Dome
By Chris Markoch | May 30, 2025
View 3 Defense Stocks That Will Profit From a Golden Dome
Analysts Are Bullish on Marvell Stock Despite Amazon Deal Concern
By Leo Miller | June 2, 2025
View Analysts Are Bullish on Marvell Stock Despite Amazon Deal Concern
ASML Keeps Buying Back Its Own Stock—Chasing Discount and Upside
By Gabriel Osorio-Mazilli | June 25, 2025
View ASML Keeps Buying Back Its Own Stock—Chasing Discount and Upside
Waste Management Gets a New Boost—A Tariff Safe Haven?
By Gabriel Osorio-Mazilli | May 28, 2025
View Waste Management Gets a New Boost—A Tariff Safe Haven?

NAGE, ADMA, KRYS, and ZLAB Company Descriptions

ADMA Biologics NASDAQ:ADMA

$18.40 +0.80 (+4.55%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$18.36 -0.04 (-0.19%)

As of 04:36 AM Eastern

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Krystal Biotech NASDAQ:KRYS

$142.58 +0.08 (+0.06%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$143.06 +0.47 (+0.33%)

As of 06/26/2025 06:18 PM Eastern

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Niagen Bioscience NASDAQ:NAGE

$13.82 +0.41 (+3.06%)

As of 06/26/2025 04:00 PM Eastern

Niagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.

Zai Lab NASDAQ:ZLAB

$36.19 -0.77 (-2.08%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$35.75 -0.44 (-1.21%)

As of 04:00 AM Eastern

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time